United States was West Pharmaceutical Services’s largest region in fiscal 2025, bringing in $1.33B of $3.07B (43%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.29B | $1.24B | $1.23B | $1.33B | |||||||||||||
| Other European Countries | $359.20M | $388.10M | $385.50M | $451.00M | |||||||||||||
| Germany | $398.70M | $406.10M | $372.50M | $380.30M | |||||||||||||
| Other | $364.30M | $348.50M | $339.00M | $353.30M | |||||||||||||
| Other Countries | — | — | — | — | |||||||||||||
| Ireland | $240.30M | $285.70M | $323.20M | $333.30M | |||||||||||||
| France | $237.90M | $282.90M | $242.20M | $226.60M | |||||||||||||
| Total | $2.89B | $2.95B | $2.89B | $3.07B |
West Pharmaceutical Services brought in $3.07B from its six regions in fiscal 2025, the year ended December 31, 2025. That was up 6.3% from $2.89B in fiscal 2024. United States was the largest at $1.33B (43.3%), ahead of Other European Countries at $451.00M (14.7%) and Germany at $380.30M (12.4%). The other three regions brought in $913.20M combined.
Compared with fiscal 2024, Other European Countries grew fastest, up 17.0% to $451.00M, while France fell the most, down 6.4% to $226.60M. From fiscal 2022 to 2025, combined revenue from these regions grew from $2.89B to $3.07B, a compound annual growth rate of 2.1%. United States' share of the total fell from 44.6% to 43.3%.
Proprietary Products was West Pharmaceutical Services’s largest segment in fiscal 2025, bringing in $2.49B of $3.07B (81%).
| Segment | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $2.41B | $2.40B | $2.33B | $2.49B | |||||||||||||
| Packaging Systems | — | — | — | — | |||||||||||||
| Contract-Manufactured Products | $480.40M | $552.50M | $558.70M | $582.00M | |||||||||||||
| Contract Manufactured Products | — | — | — | — | |||||||||||||
| Contract Manufacturing | — | — | — | — | |||||||||||||
| Delivery Systems | — | — | — | — | |||||||||||||
| Intersegment Elimination | — | — | — | — | |||||||||||||
| Corporate & Eliminations | — | — | — | — | |||||||||||||
| Other Unallocated Items | — | — | — | — | |||||||||||||
| Total | $2.89B | $2.95B | $2.89B | $3.07B |
West Pharmaceutical Services brought in $3.07B from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 6.3% from $2.89B in fiscal 2024. Proprietary Products was the largest at $2.49B (81.1%), ahead of Contract-Manufactured Products at $582.00M (18.9%).
Compared with fiscal 2024, Proprietary Products grew 6.8% to $2.49B and Contract-Manufactured Products grew 4.2% to $582.00M. From fiscal 2022 to 2025, combined revenue from these segments grew from $2.89B to $3.07B, a compound annual growth rate of 2.1%. Proprietary Products' share of the total fell from 83.4% to 81.1%.
Pharmaceutical Packaging was West Pharmaceutical Services’s largest revenue line in fiscal 2009, bringing in $637.30M of $1.06B (60%).
| Breakdown | FY 2009 |
|---|---|
| Pharmaceutical Packaging | $637.30M |
| Healthcare Devices | $165.90M |
| Disposable Medical Components | $104.60M |
| Consumer Products | $57.40M |
| Injection & Administration Systems | $42.90M |
| Laboratory & Other Services | $34.10M |
| Tooling & Other Services | $18.80M |
| Total | $1.06B |
West Pharmaceutical Services brought in $1.06B from its seven revenue lines in fiscal 2009, the year ended December 31, 2009. Pharmaceutical Packaging was the largest at $637.30M (60.1%), ahead of Healthcare Devices at $165.90M (15.6%) and Disposable Medical Components at $104.60M (9.9%). The other four revenue lines brought in $153.20M combined.
West Pharmaceutical Services (WST) reports its revenue by geography, by segment and by breakdown. In fiscal 2025, United States was its largest region, bringing in $1.33B (43.3% of the total), followed by Other European Countries at $451.00M (14.7%).
United States was West Pharmaceutical Services' largest region in fiscal 2025, bringing in $1.33B, or 43.3% of the $3.07B total across its six regions.
Proprietary Products was West Pharmaceutical Services' largest segment in fiscal 2025, bringing in $2.49B, or 81.1% of the $3.07B total across its two segments.
Pharmaceutical Packaging was West Pharmaceutical Services' largest revenue line in fiscal 2009, bringing in $637.30M, or 60.1% of the $1.06B total across its seven revenue lines.
Among West Pharmaceutical Services' regions that make up at least 2% of revenue, Other European Countries grew fastest in fiscal 2025, up 17.0% from $385.50M to $451.00M.
Every figure comes from West Pharmaceutical Services' annual financial filings, as reported. Each line keeps the name West Pharmaceutical Services gives it, and years follow its fiscal calendar.
West Pharmaceutical Services' revenue by geography goes back to fiscal 2009, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.